Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFB-088 plus riluzole vs placebo plus riluzole in bulbar-onset amyotrophic lateral sclerosis
2021-003875-32Phase 2Completed
- Sponsor
- InFlectis BioScience
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing IFB-088 plus riluzole with Placebo plus riluzole (2 arms). Primary endpoint: Safety of IFB-088 50 mg/day. Started Oct 2021; status: completed.
02
Drugs
Icerguastat
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-003875-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003875-32.